FDA Clears Second At-Home Cervical Cancer Screening Kit
The FDA cleared another at-home cervical cancer screening kit on April 17, 2026, expanding access for women who face barriers to in-office testing. The move follows growing demand for self-collection options.
The FDA cleared a second at-home cervical cancer screening kit on April 17, 2026, giving more women access to testing outside a clinical setting.
The clearance follows the approval of the first such kit and reflects growing demand for self-collection options. Women who face barriers to in-office care, including cost, transportation, or discomfort with pelvic exams, now have another path to screening.
Cervical cancer is largely preventable when caught early. Regular screening through Pap smears or HPV tests has driven down death rates significantly over the past several decades. But access gaps remain, particularly in rural areas and among uninsured patients.
At-home kits allow women to collect their own samples and mail them to a lab. Results are returned through a secure online portal or by mail. Positive results prompt follow-up with a healthcare provider.
The FDA said the new kit met accuracy standards comparable to in-office collection. Health advocates called the clearance a step toward closing screening gaps.
The American Cancer Society estimates that about 13,000 new cases of cervical cancer are diagnosed in the United States each year. Expanding access to screening is a key part of efforts to reduce that number.
